According to the company, the Neuropath guide catheter line is designed with a flexible and visible tip that allows for ready vascular access, while maintaining stability. This design is intended to allow neurointerventionalists with better vessel access and greater vessel selection in treating patients with complex anatomies.
John Kilcoyne, chairman and CEO of Micrus Endovascular, said: “The Neuropath marks our entry into the guide catheter market and therefore represents a 100% incremental revenue opportunity for us. The Neuropath is another example of Micrus’s commitment to the development of products that deliver clinical advantages to our physicians while bolstering our non-embolic product portfolio.”